Observation on Effect of Methimazole Combined with Propranolol Sustained Release Tablets in the Treatment of Hyperthyroidism and Analysis of the Influence of FT4 and FT3 Levels  

作　　者：MAJianhui 

机构地区：[1]Pingshan County People's Hospital, Shijiazhuang 050400, China

出　　处：《外文科技期刊数据库(文摘版)医药卫生》2022年第10期096-100,共5页

摘　　要：Objective: To evaluate the efficacy of methimazole combined with propranolol sustained-release tablets in the treatment of hyperthyroidism and its influence on FT4 and FT3 levels. Methods: Eighty-six hyperthyroidism patients who are fully aware of the research content and voluntarily participate in the research were selected as the research samples. The first patient and the last patient were treated in our hospital in January 2021 and December 2021, respectively, and they were equally divided into two groups. There were two groups, one group was named as the control group, the other group was named as the observation group, and the treatment drug was methimazole combined with propranolol sustained-release tablets. Results: The indexes selected in the study were thyroid index, serum index, therapeutic effect and adverse reactions. The data obtained were analyzed and compared between groups, and the observation group was better than the control group (P 0.05). Conclusion: When treating patients with hyperthyroidism clinically, the scheme of methimazole combined with propranolol sustained-release tablets can not only effectively improve the thyroid index of patients, but also relieve their related symptoms, which has high clinical application value.

关 键 词：HYPERTHYROIDISM METHIMAZOLE Propranolol sustained-release tablets FT4 and FT3 levels 

分 类 号：R581.1[医药卫生—内分泌]